Amelia is a four-time UK biotech CFO with a career built entirely inside the drug-development ecosystem, from Solivant and Arclight through her portfolio stint at Northlight Genomics and into her current Helix seat. She has led a Series A end-to-end at Stellaris, exited Arclight via a target-side trade sale, and closed Helix's Series B eighteen months ago — a rare combination of raise, exit and scale-up experience at pre-clinical and clinical-stage oncology assets. Her tenure at Helix is now maturing, she has recently added two NED roles, and she has publicly said she prefers the pre-Series A build phase. For a Cambridge- or London-based oncology brief at NorthVale's stage, she is as close to a template match as this market produces.

Daniel is a Cambridge-based biotech finance operator whose career has moved cleanly from Finance Director roles at Pendragon Bio and Halcyon Therapeutics into SVP Finance seats at three consecutive drug-development companies, with an interim CFO stint at Glasslake Therapeutics in between. He led the Series A at Ridgeline Bio inside the company, sat target-side on Glasslake's trade sale, and currently runs the finance function at Kestrel Biopharma reporting to the board. For a UK pre-Series A oncology CFO brief he is unusually on-target: right stage instinct, right therapeutic area, right ecosystem relationships, and signalling openness.

Priya is a two-time UK biotech CFO with a clean pre-Series A to Series B arc at Embercast and Wintergreen, plus a target-side trade sale at Embercast that closed to a mid-cap acquirer. She started her career in pharma finance at Linden, moved into her first CFO seat at Brookmere at seed stage, and has since built two finance functions from a blank sheet including R&D tax credit programmes and EIS/SEIS structuring. The Tessera Therapeutics UK chair seat gives her current oncology board exposure, and Wintergreen is now four years in with the Series B deployed — the timing lines up. For a pre-Series A oncology CFO brief, she is the shape of candidate the search was written for.

Jonas is an Oxford-based CFO with a clean four-company run through UK drug-development biotechs, currently Group CFO at Faraway Pharma and chair at Larchmont Bio. He led the Series A at Ashstone Biopharma and the Series B at Calderwood Therapeutics from the inside, and carried a Head of BD remit alongside finance at Helix Therapeutics. His trajectory is unusually well-matched to a UK pre-Series A oncology CFO seat: he has done exactly this job, at this stage, in this ecosystem, more than once. The chairman role suggests bandwidth for a new operating mandate and appetite for earlier-stage work again.

Rosa is a Cambridge-based biotech CFO whose entire career has been spent inside UK drug-development companies, starting as a project accountant at Meridian Oncology and moving through Quill Bio, Solivant, Arclight and now Verdant Biosciences. She led the Quill Bio Series A from the inside, sat on the target side of Arclight's strategic conversations, and is currently running Verdant's finance function through its own Series A prep. What makes her interesting for NorthVale is the near-exact stage and sector overlap — she is doing this job, in this ecosystem, right now — combined with a history of building finance functions from a blank sheet.

Clara is a UK biotech CFO with an unusually clean oncology-therapeutics track record: Meridian Oncology, Quill Bio, Solivant Therapeutics, Arclight Pharma and now Verdant Biosciences. She has led one Series A end-to-end from the CFO seat and supported two earlier venture raises as Finance Director, and has built finance functions from scratch twice. For a pre-Series A oncology CFO brief with a raise imminent, her profile is close to a template match — the open question is whether she is movable two years into Verdant.

Mira is a Cambridge-based biotech CFO whose career has tracked the UK oncology cluster from Meridian Oncology through Iverline Bio, Yarrowfield Therapeutics and Brookmere Bio, with a current VP Finance seat at Linden Pharma that looks like a holding pattern rather than a destination. She has personally led two Series A raises, one target-side trade sale conversation at Brookmere, and has built finance functions from scratch twice. For a pre-Series A oncology CFO brief with a live raise ahead, her profile is almost unusually well-matched — the question is timing and package, not fit.

Jasper is a two-time UK biotech CFO with a corporate development spine — banking at Wintergreen Biotech, a founder stint at Saltford Pharma, then strategy roles at Pendragon Bio and Halcyon Therapeutics before stepping up to CFO at Ridgeline Bio and now Cantor Pharma. He has personally led a Series A from inside the company at Ridgeline and has run target-side M&A processes at Pendragon. For a pre-Series A oncology mandate needing a CFO who can build the function, run the raise and hold the board, his shape is unusually close to the brief.